AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03846141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrogen
Description: Inhalation of 4% hydrogen for 20 min per day during 7 days
Study NCT04419883 — intervention group
Intervention type: DEVICE
Intervention: McMurray Enhanced Airway
Description: Provider Satisfaction of a New, Flexible Extended-Length Pharyngeal Airway to Relieve Upper Airway Obstructive During Deep Sedation: A Pilot Study
Study NCT02036879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loestrin (norethindrone acetate and ethinyl estradiol)
Description: This is an optional substudy that females participating in the main study can choose to participate in. Loestrin, an oral contraceptive or birth control pill, will be prescribed and taken daily for approximately 2 months.
Study NCT02825784 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Renastart
Description: Renastart: specially formulated to meet the unique nutritional needs of children from birth to 10 years with chronic kidney disease (CKD).
Study NCT01439152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-9343
Description: BAY94-9343 was administered intravenously in this study. The starting dose for this first-in-man study was 0.15 mg/kg administered as a 1 hour infusion every 21 days.
Study NCT01439152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-9343 (Expansion)
Description: BAY94-9343 was administered intravenously in this study. The dose for this expansion cohort was 5.5mg/kg administered as a 1 hour infusion every 21 days.
Study NCT01439152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-9343 (1.8 mg/kg)
Description: BAY94-9343 was administered intravenously in this study. The dose for this cohort was 1.8 mg/kg administered as a 1 hour infusion every week for 3 weeks.
Study NCT02858622 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: fentanyl
Study NCT02858622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Study NCT01524575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine and oxaliplatin
Description: Excision repair cross-complementation group 1 (ERCC1) protein and mRNA expression predicts response to oxaliplatin - patients whose cancers make small amounts of ERCC1 are much more likely to respond to cisplatin than those whose tumors produce large amounts.
Study NCT04008472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedecine
Description: Initiation of tele-medical consultation with the resident, a caregiver for the nursing home, the referring physician and geriatrician téléexpert. After a overall geriatric assessment in nursing homes by UPSAV the first teleconsultation is organized within 10 days. Subsequent visits are scheduled every 3 months for 12 months. Spontaneous visits can be requested at the initiative of the referring physician.
Study NCT03606902 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group f : Epidural catheter insertion
Description: Infiltrate the skin with local anesthetic lidocaine approximately 1 cm lateral to the inferior aspect of the targeted spinous process , epidural needle tip is midline at the junction of the lamina and spinous process . The needle is withdrawn and advanced with the same medial angle but in small increments cephalad to the same depth. Either bone or ligamentum flavum is contacted. If bone is contacted, the needle is redirected cephalad and advanced. If bone is no longer contacted and the depth exceeds the depth previously noted, the epidural needle stilette is removed. loss-of-resistance syringe is attached to the needle Once attained, stabilize the epidural needle and thread the catheter. Secure the catheter using a sterile locking device and adherent dressings.
Study NCT03606902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group F: Continous epidural infusion of bupivacaine plus fentanyl
Description: Epidural injection of bolus of 15 ml total Volume of 0.0625%bupivacaine with 1 µg /Kg Fentanyl initial bolus, then from the 1st hour continuous epidural infusion of 0.0625% bupivacaine with µ/Kg/h Fentanyl fixed for the next 5 hour during operation and in the recovery room after recovery of general anesthesia then stop epidural infusion. (Total infusion time 6 hours=maximum hours needed for nephrectomy surgery)
Study NCT03606902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group LF :Continous epidural infusion of decreasing doses of fentanyl plus pubivacaine
Description: Epidural injection of bolus of 15 ml total Volume of 0.0625%bupivacaine with 1 µg/Kg Fentanyl initial bolus, then continuous IV infusion of 0.0625%bupivacaine with 1 µg/Kg/h Fentanyl for the 1st hour then continuous epidural infusion of 0.0625%bupivacaine with 0.5 µg/Kg/h Fentanyl during the 2nd hour, then 0.0625%bupivacaine with 0.25 µ g/Kg/h Fentanyl for the 3rd hour then continue the same infusion volume and dose (0.0625%bupivacaine with 0.25Mg/Kg/h Fentanyl) for the next 3 hours during operation and in the recovery room after recovery of general anesthesia then stop epidural infusion. (Total infusion time 6 hours=maximum hours needed for nephrectomy surgery)
Study NCT03606902 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group L f : Epidural catheter insertion
Description: Infiltrate the skin with local anesthetic lidocaine approximately 1 cm lateral to the inferior aspect of the targeted spinous process , epidural needle tip is midline at the junction of the lamina and spinous process . The needle is withdrawn and advanced with the same medial angle but in small increments cephalad to the same depth. Either bone or ligamentum flavum is contacted. If bone is contacted, the needle is redirected cephalad and advanced. If bone is no longer contacted and the depth exceeds the depth previously noted, the epidural needle stilette is removed. loss-of-resistance syringe is attached to the needle Once attained, stabilize the epidural needle and thread the catheter. Secure the catheter using a sterile locking device and adherent dressings.
Study NCT01781546 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: drug-eluting balloon (DEB)
Description: The length of the DEB is chosen so that the lesion and 2mm from both ends are covered by the DEB. If needed, several DEBs can be used to cover the whole lesion. The diameter of the DEB and the pressure used is chosen so that the balloon-artery -ratio is 0.8-1.0. In case of a flow limiting dissection, significant recoil or coronary perforation, a provisional BMS is implanted (stent-artery -ratio 1.1) and the post dilatation is performed if indicated (the lesion length is >20mm or stent malapposition is suspected).
Study NCT01781546 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bare-metal stent (BMS)
Description: The BMS is implanted after predilatation (stent-artery -ratio 1.1) to cover the whole lesion and the postdilatation is performed if indicated (the lesion length >20mm or stent malapposition is suspected).
Study NCT02233777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin capsules 150 mg of Dexa Medica
Description: Each capsule contains 150 mg of pregabalin. Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
Study NCT02233777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin capsules 150 mg of Pfizer Manufacturing Deutschland
Description: Each capsule contains 150 mg of pregabalin. Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
Study NCT04403334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin Ophthalmic
Description: 0.1 ml of unpreserved 0.5% levofloxacin
Study NCT04403334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Ophthalmic
Description: 0.1 ml of unpreserved 0.5% moxifloxacin
Study NCT01488890 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus
Description: 0.5 mL, Subcutaneous
Study NCT01488890 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Yellow Fever
Description: 0.5 mL, Subcutaneous
Study NCT01488890 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Yellow Fever
Description: 0.5 mL, Subcutaneous
Study NCT04407754 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inositol supplement
Description: Inositol supplements given to inositol arm
Study NCT04407754 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: Placebo supplement given to placebo arm
Study NCT02780648 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation
Study NCT01439152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-9343 (2.2 mg/kg)
Description: BAY94-9343 was administered intravenously in this study. The dose for this cohort was 2.2 mg/kg administered as a 1 hour infusion every week for 3 weeks.
Study NCT03542773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL Injection
Description: 18F-DCFPyL with whole body PET/CT scan
Study NCT01546350 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: PGD
Description: array CGH after blastocyst biopsy
Study NCT01546350 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PGD
Description: PGD using blastocyst biopsy and testing of the biopsy by array CGH
Study NCT01558011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine, Oxaliplatin, Docetaxel
Description: Capecitabine: 500 mg film coated tablets; Oxaliplatin: 50 mg/ 10 ml; Docetaxel: 20 mg / 0.5ml vial.~Dosing Regimena: total of 6 cycles of modified XELOX regimen repeats every 2 weeks, and followed by 4 cycles of TX repeats every 3 weeks. After 10 cycles of treatment, patients may continue to treat with either of the regimen, preferably the one having the best efficacy.
Study NCT02868866 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate Intervention
Description: Committees from 40 churches will be trained in the Faith, Activity, and Nutrition program by Community Health Advisors. The training focuses on helping churches create healthier church environments for physical activity and healthy eating using Cohen's structural model of health behavior as a guide. Each church committee participates in a full-day training and submits a program plan and budget. Churches receive materials to support implementation of the program. After the full-day training, trained churches receive 12 monthly technical assistance calls to help them implement their program plan. The church coordinator receives 8 calls and the pastor receives 4 calls over the 12 months. In Phase 2, the intervention is open to any church in the SC Conference of the United Methodist Church.
Study NCT02763787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 3-202
Description: single rising oral doses (10 mg, 30 mg, 50 mg, 100 mg, 200 mg, 400 mg, 800 mg)
Study NCT02763787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Identical placebo
Study NCT01496482 — intervention group
Intervention type: OTHER
Intervention: Only measurements done on subjects in both groups.
Description: As study compared specific diagnostic procedures, no intervention was done or compared.
Study NCT02667587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT02667587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Study NCT02667587 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Temozolomide
Study NCT02667587 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study NCT02667587 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy
Study NCT02667587 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nivolumab Placebo
Study NCT03343301 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bemarituzumab
Description: Administered by intravenous infusion over approximately 30 minutes
Study NCT03343301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified FOLFOX6
Description: Modified FOLFOX6 regimen consists of the following:~* Oxaliplatin 85 mg/m² IV infusion over 120 minutes~* Leucovorin 400 mg/m² IV infusion over 120 minutes, or 200 mg/m² levo-leucovorin if leucovorin is unavailable~* 5-fluorouracil (5-FU) 400 mg/m² bolus over approximately 5 minutes then 5-FU 2400 mg/m² as a continuous IV infusion over approximately 48 hours.
Study NCT03430206 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula
Description: While applied, the cannula will deliver high-flow rate oxygen, air, or a mixture of variable oxygen concentration (21-100%) depending on the surgical conditions and requirements. The rate will be set at 2L/kg/min with a maximum of 70L/min. This will be only for the duration of the surgery or procedure.
Study NCT00551941 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BMP-7 in adjunct to fresh frozen allograft
Description: non-union of diaphysary tibial fractures treated with BMP-7 in adjunct to fresh frozen allograft
Study NCT00551941 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: allograft together with DBM
Description: non-union of diaphysary tibial fractures treated with allograft together with DBM
Study NCT03536299 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual-task gait
Description: During the training sessions, you will participate in gait training with a physical therapist (PT). You will be asked to walk in 2-minute bouts and you will be provided with adequate rest breaks to help manage your fatigue levels. In addition to performing the gait training activities, you will be asked to perform thinking tasks at the same time. These pre-recorded questions or prompts will be provided to you through headphones and a portable music player. This is to help ensure that the PT is able to focus on giving you feedback about your walking ability and answers to the thinking tasks, and on your safety. At the end of each session, you will have walked for a total walking time of 20 minutes.
Study NCT03536299 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single-task gait
Description: During the training sessions, you will participate in gait training with a physical therapist (PT). You will be asked to walk in 2-minute bouts and you will be provided with adequate rest breaks to help manage your fatigue levels. At the end of each session, you will have walked for a total walking time of 20 minutes.
Study NCT04266067 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PNF exercise
Description: Proprioceptive neuromuscular facilitation (PNF) is a form of neuromuscular retraining type containing the stimulation of sensory receptors to provide information about the body position and movement to facilitate the intended movement
Study NCT04266067 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Frenkel exercise
Description: The Frenkel exercises consist of a series of slow, repetitive movements performed in different positions while lying, sitting and standing.
Study NCT02530515 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ex Vivo-activated Autologous Lymph Node Lymphocytes
Description: Given IV
Study NCT02530515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01516905 — intervention group
Intervention type: DRUG
Intervention: NM404
Description: injection of either 2.0mCi or 5.0mCi I-124 NM404
Study NCT04730102 — intervention group
Intervention type: PROCEDURE
Intervention: Rectal washout
Description: Rectal washout is performed intraoperatively before transection and means irrigation of the rectum following the closure of the rectal lumen below the tumour with a purse string suture. Rectal washout is performed with a total of 500 ml sterile water. Fluid samples are collected after every 100 ml by instilling 50 ml of saline after each washout. A sixth sample is collected from the presacral cavity.
Study NCT01625299 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gluten and dry milk
Description: 0.5 g/kg/day of gluten 0.5 g/kg/day of dry milk
Study NCT01625299 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rice flour 1.0 g/kg/day
Study NCT04386811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: A total of 24 otherwise medically healthy individuals with ADHD will be studied as outpatients. All subjects will undergo neurocognitive assessments of attention/vigilance, spatial working memory, and reversal learning both before and after subjects' daily dosing with their currently prescribed stimulant medication on both calcitriol and placebo pretreatment days using a randomized, double-blind, placebo controlled, within-subject, two-day study design.
Study NCT04386811 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A total of 24 otherwise medically healthy individuals with ADHD will be studied as outpatients. All subjects will undergo neurocognitive assessments of attention/vigilance, spatial working memory, and reversal learning both before and after subjects' daily dosing with their currently prescribed stimulant medication on both calcitriol and placebo pretreatment days using a randomized, double-blind, placebo controlled, within-subject, two-day study design.
Study NCT03726710 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blood Pressure measurement and pharmacy
Description: Blood Pressure monitoring by barber, Blood pressure measurement and management by pharmacist in person and through telemedicine
Study NCT04497454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EIT-Group
Description: A mechanical ventilation strategy with the main goal to maintain DP \< 16 cmH2O
Study NCT04497454 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ARDSNet
Description: Low PEEP-FiO2 table ARDS Network ventilation protocol
Study NCT03617341 — intervention group
Intervention type: PROCEDURE
Intervention: Brain MRI
Description: Brain MRI will be taken at the time of initial diagnosis, first- and second-line treatment failure. Therefore, the investigators expect that early detection of brain metastases before the onset of symptoms will affect the overall prognosis of MBC patients.
Study NCT05576194 — intervention group
Intervention type: DEVICE
Intervention: TauroPace
Description: All the hardware (leads, suture sleeves, pulse generator) is washed and the device pocket irrigated with an adjunct antimicrobial solution containing Taurolidine (TauroPace™, Tauropharm, Bavaria, Germany), during any invasive procedure (new implantation, pulse generator replacement, lead repositioning or insertion, system upgrade or downgrade, revision) involving a CIED system since January 2019
Study NCT05576194 — intervention group
Intervention type: DEVICE
Intervention: Hydrogen Peroxide
Description: All the hardware (leads, suture sleeves, pulse generator) was washed and the device pocket irrigated with an adjunct antimicrobial solution containing 3% hydrogen peroxide (H2O2) during any invasive procedure (new implantation, pulse generator replacement, lead repositioning or insertion, system upgrade or downgrade, revision) involving a CIED system at the authors' institute before 01/01/2020
Study NCT05576194 — intervention group
Intervention type: DRUG
Intervention: Taurolidine
Description: All the hardware (leads, suture sleeves, pulse generator) was washed and the device pocket irrigated with an adjunct antimicrobial solution containing taurolidine in a galenic formulation during any invasive procedure (new implantation, pulse generator replacement, lead repositioning or insertion, system upgrade or downgrade, revision) involving a CIED system at the authors' institute before 01/01/2019
Study NCT03207100 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Analgesia-first minimal sedation
Description: Remifentanil will be administered by IV infusion and maintained at a dose of 0.025 μg/kg/min in non-mechanically ventilated patients and a dose of 0.05 μg/kg/min in mechanically ventilated patients. BP will be measured after 10 min of continuous infusion.If systolic BP is still ≥ 140 mmHg, then dexmedetomidine will be applied using an infusion pump at a dose of 0.2 μg/kg/h. BP will be measured again after 15 min of continuous infusion of dexmedetomidine. If systolic BP is still ≥ 140 mmHg, the dose of dexmedetomidine can be increased 0.1 μg/kg/h to the maximum of 0.6 μg/kg/h.If the maximum dose of dexmedetomidine does not lower blood pressure, use routine blood pressure reduction programs in each center to reduce blood pressure to the target range. Mechanically ventilated patients will be given a rapid remifentanil (0.5 μg/kg) infusion to reduce procedure-related pain.
Study NCT03207100 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Antihypertensive treatment
Description: Routine antihypertensive treatment will be performed in accordance with the protocol of each respective research center. Urapidil, nicardipine, and labetalol will be used in this group. Urapidil will be used as follows: a slow IV injection of 10-15 mg and then IV pumping for maintenance at an initial rate of 2 mg/min, adjusted according to BP to a maximum of 9 mg/min. Nicardipine will be used as follows: IV pumping at 0.5μg/kg/min adjusted according to BP to a maximum of 6μg/kg/min. Labetalol will be used as follows: IV infusion for maintenance at 1-4 mg/min until the aim is reached.The mechanically ventilated patients in the control group will be administered a rapid physiological saline infusion as a controlled pretreatment.
Study NCT02038491 — intervention group
Intervention type: PROCEDURE
Intervention: regional anesthesia
Description: Spinal, epidural, combined spinal epidural, nerve blocks
Study NCT03728777 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Resveratrol
Description: Resveratrol supplementation 1000 mg /day or placebo
Study NCT03728777 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: Resveratrol supplementation 1000 mg /day or placebo